Tags : Inhibitor BBT-877


Boehringer Ingelheim Signs a Worldwide License Agreement with Bridge Biotherapeutics

Shots: Bridge to receive $50.66M as up front and near-term payments, up to $1.23B based on development, regulatory, and commercial milestones and royalties on sales The focus of the collaboration is to develop Bridge’s BBT-877 candidate and expand BI’s pipeline of fibrosing interstitial lung diseases in developing therapies for patients with Idiopathic Pulmonary Fibrosis (IPF)  […]Read More